Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. - Wikidata - wikimedia - TriplyDB

Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.

Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.

http://www.wikidata.org/entity/Q37418080

about

Prostate cancer biomarkers: Are we hitting the mark?The role of prostate cancer biomarkers in undiagnosed men.Epigenetic risk score improves prostate cancer risk assessment.Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.The Use of Biomarkers in Prostate Cancer Screening and Treatment.Genomic biomarkers in prostate cancer Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients

P2860

Q28071654-D59DC210-3B38-46E2-AA58-F786CD9660BF Q39140686-09BE8261-B9BF-46C6-BC08-5352221452C1 Q43152996-D44355E2-9E69-41A8-A0C4-4F125A8072D9 Q49710514-6CAAF7A3-8DB5-4642-B169-F80E5051031C Q52689045-D570CF99-315F-4560-B718-CE4E02877025 Q57112354-86DC31A5-6B9F-41E7-850C-5E6911FE19D8 Q58101953-7B532022-1616-40D0-A55E-4287CCDBF350

P2860

Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.

http://www.wikidata.org/entity/Q37418080

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Risk score predicts high-grade ...... hologically negative biopsies.

@en

Risk score predicts high-grade ...... hologically negative biopsies.

@nl

type

label

Risk score predicts high-grade ...... hologically negative biopsies.

@en

Risk score predicts high-grade ...... hologically negative biopsies.

@nl

prefLabel

Risk score predicts high-grade ...... hologically negative biopsies.

@en

Risk score predicts high-grade ...... hologically negative biopsies.

@nl

P1433

Q37418080-D3CEF628-D917-4CE0-A985-1C6A7A30D994

P1476

Q37418080-975813C8-D376-409A-8070-3D83053317C0

P2093

Q37418080-0058F97D-BCE7-4F37-9D58-9D4300A8DAC7

Q37418080-74EEF492-40DA-46FE-9DA9-E0514BEF5EB8

Q37418080-8A8C23BD-88FB-441E-8440-318DE3E13495

Q37418080-FC5B0D6F-854D-4BB0-95AF-84C85457D76D

P2860

Q37418080-1322FBCD-AFFA-4026-B97C-6B4676ABF5C6

Q37418080-281EDB53-5D29-4922-8F8A-16B65CE57E2D

Q37418080-2A127477-7B34-407D-913F-A9A845E6FB8B

Q37418080-3B48EE7D-9DA7-4EF7-BBD5-3548174F6D5E

Q37418080-3C51F248-2C00-4FEA-81EF-73F3FC90FC31

Q37418080-468430F0-C6A3-447A-9D2F-56E980A5F2E6

Q37418080-473E2B08-38B9-4937-B674-BAC376516155

Q37418080-49324029-60E9-48A8-9A6D-DADA9345213C

Q37418080-4B976F0F-5EF0-46C6-80BA-AE8409DC9C33

Q37418080-501510CF-8627-4538-A028-D4C6542CEDF9

P304

Q37418080-960FF61B-C2B0-4B1D-99DE-816B63DA7C4A

P31

Q37418080-E10F0954-D0E3-4B27-9FBD-B09241654DF6

P356

Q37418080-43FB4FE9-AB77-4B45-8EAC-BD8CDA300E33

P433

Q37418080-6C6B8138-F46B-4B41-AF31-E4E9C255E196

P478

Q37418080-247CA6A1-6932-42F6-8930-8C5E86E09327

P50

Q37418080-A539E089-D570-4C4D-8A3D-600712D9483A

Q37418080-CA396672-8AFE-4473-A2F5-BB834907EEB6

P577

Q37418080-97EEA510-3307-4202-97F6-20BCF69A6C37

P698

Q37418080-6296FBC6-B0EE-4C78-BDFB-99829FACC663

P921

Q37418080-AD0EDFB2-21AE-4C00-A7A8-7C79068055B4

Q37418080-EFE32785-9ADB-4E4A-A182-5C1EF53967D7

P932

Q37418080-D0FA0657-9186-4C14-A616-C126887E9865

P356

P1433

P1476

Risk score predicts high-grade ...... hologically negative biopsies.

@en

P2093

Alan W Partin

http://www.w3.org/2001/XMLSchema#string

Jonathan I Epstein

http://www.w3.org/2001/XMLSchema#string

Leander Van Neste

http://www.w3.org/2001/XMLSchema#string

Wim Van Criekinge

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study.

Complications after prostate biopsy: data from SEER-Medicare.

A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Decision curve analysis: a novel method for evaluating prediction models

Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

P304

1078-1087

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.23191

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Grant D. Stewart

David J Harrison

P577

2016-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27121847

http://www.w3.org/2001/XMLSchema#string

P921

DNA methylation

P932

5111760

http://www.w3.org/2001/XMLSchema#string